10975 North Torrey Pines Road
About Ambrx, Inc.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
49 articles with Ambrx, Inc.
Ambrx Announces Formation and Members of Scientific Advisory Board.
Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.
Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
- 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU - Multiple Global Phase 2/3 Trials to Begin Early 2021
Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics
Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced the successful closing of an oversubscribed US$200 million crossover financing round.
4/15/2020The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.
Ambrx Inc. and Sino Biopharmaceutical Limited announced a joint collaboration to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms.
Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates
Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx's internally developed site-specific antibody drug conjugates (ADCs).
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
Ambrx Inc. announced that Bristol-Myers Squibb Company has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure.
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of innovative protein therapeutics and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a global research and development collaboration.
TRACON will receive an upfront payment of $3M, and is eligible to receive development and regulatory milestones of up to $10.5M, and commercial sales milestones of up to $130M.
Wuxi Biologics Congratulates Ambrx, Inc. And ZMC For Successful Dosing Of A Novel Antibody-Drug Conjugate In Australia
Ambrx, Inc. And Zhejiang Medicine Co. Ltd Initiated ARX788 First-In-Human Phase I Clinical Trial In Cancer Patients
Fosun Pharma, HOPU Investments, CEL Healthcare Fund, And WuXi PharmaTech Co., Ltd. To Jointly Acquire U.S. Innovative Biotechnology Company Ambrx, Inc.